Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-39220675 · 1 trial · 1 indication
The AcR was an objective measurement of nasal congestion that assessed nasal cavity geometry (that is, MCA) and changes in dimensions of nasal cavity. The AUC of MCA was used as response variable to assess treatment effect. AUC was adjusted for Baseline MCA scores. Baseline MCA was defined as minimum mean MCA at pre-dose (approximately 2 hours before Environmental Exposure Chamber \[EEC\] entry) resulting from 3 measurements on both, left and right nostrils in each of the treatment periods. The AUC of MCA was baseline-adjusted, by subtracting the Baseline value from each of the post-treatment times before calculating the AUC.
| Arm | Type | Description |
|---|---|---|
| JNJ-39220675 then Pseudoephedrine then Placebo | EXPERIMENTAL | Single-dose of JNJ-39220675 will be administered as 1 milliliter (ml) of 10 milligram/milliliter (mg/ml) solution orally along with placebo tablet in first treatment period; after that in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 milligram (mg) pseudoephedrine tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| JNJ-39220675 then Placebo then Pseudoephedrine | EXPERIMENTAL | Single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| Placebo then JNJ-39220675 then Pseudoephedrine | EXPERIMENTAL | Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| Placebo then Pseudoephedrine then JNJ-39220675 | EXPERIMENTAL | Single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| Pseudoephedrine then JNJ-39220675 then Placebo | EXPERIMENTAL | Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution along with placebo tablet; and then single-dose of 1 ml placebo solution will be administered orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| Pseudoephedrine then Placebo then JNJ-39220675 | EXPERIMENTAL | Single-dose of 1 ml placebo solution will be administered orally along with 60 mg pseudoephedrine tablet in first treatment period; after that, in second treatment period, single-dose of 1 ml placebo solution will be administered orally along with placebo tablet; and then single-dose of JNJ-39220675 will be administered as 1 ml of 10 mg/ml solution orally along with placebo tablet in third treatment period. A washout period of at least 6 days will be maintained between each treatment period. |
| Name | Type | Description |
|---|---|---|
| Placebo | OTHER | Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods. |
| JNJ-39220675 | DRUG | Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods. |
| Pseudoephedrine | DRUG | Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods. |
Inclusion Criteria: * Participants must have a clinical history of seasonal allergic rhinitis with seasonal onset and offset of nasal allergy symptoms at least during each of the last two ragweed allergy seasons * Participants must have documentation of a positive skin test within 12 months of Scre...
Top 1 of 3 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 1 | PHASE3 | LY3650150 |
JNJ-39220675 is an investigational small molecule being studied for the treatment of allergic rhinitis. It was evaluated in a Phase 2 clinical trial that enrolled 53 participants with allergic rhinitis. It is not an approved therapy and remains in clinical development for this respiratory indication.
JNJ-39220675 targets HRH3, the histamine H3 receptor, and acts as an antagonist at that receptor. By blocking HRH3, the compound is designed to modulate histamine signaling relevant to allergic rhinitis. HRH3 antagonism is the mechanism under investigation for this asset.
JNJ-39220675 is being developed by Johnson & Johnson, which trades on the New York Stock Exchange under the ticker JNJ. The company sponsored the Phase 2 study of the compound in allergic rhinitis. Johnson & Johnson is the sole developer identified for this asset.
JNJ-39220675 is in Phase 2 development. It is an investigational small molecule and has not been approved for any indication. The Phase 2 trial evaluating it in allergic rhinitis has been completed, and no active trials of the compound are currently listed.
JNJ-39220675 was studied in one completed Phase 2 trial, NCT00804687, titled An Efficacy Study of JNJ-39220675 and Pseudoephedrine in Participants With Allergic Rhinitis. The trial enrolled 53 participants aged 18 years and older in Canada, was randomized and controlled, and included both sexes.